Australasia-based EBOS Group has won a tender to be the exclusive third-party distributor of pharmaceutical products to more than 400 Chemist Warehouse and My Chemist stores across Australia.
The supply agreement will take effect on 1 July 2019 and will last for five years with the possibility of a three year extension. EBOS Group believes the deal will generate approximately AUS$1bn in revenue in the first year.
EBOS Group CEO John Cullity said: “To be selected as a trusted partner by Chemist Warehouse Group reinforces our capital investment strategy and reflects the efficiencies we have made over a number of years to our operations.
“It’s a great endorsement of EBOS’s wholesale pharmacy business, and reflects the high level of expertise and service standards that we offer the industry more broadly.
“Continuing to grow our Healthcare business remains a high priority for the Group and partnering with Chemist Warehouse Group will be a natural progression of that. We are confident that EBOS will generate an acceptable return on capital from this new business.”
The company’s chairman Mark Waller said: “Today’s announcement is a strong validation of that investment and we’re very well equipped to meet growing demand across the entire industry, including from our existing customers, and continue to uphold the high standards we set.”
EBOS Group specialises in marketing, wholesaling and distributing medical and animal care products in Australasia; it has a whole sub-section that focuses on institutional healthcare called EBOS Healthcare.
The company works with prominent local names such as Symbion, Ventura Health, Intellipharm and Onelink. In November last year, it acquired a 14.1% share in MedAdvisor, a leading Australian digital medication management company connected with more tahn 900,000 users and 2,600 pharmacies, for AUS$10.5m.
EBOS Group has 3,000 employees across 52 locations in Australasia, primarily in New Zealand and Australia and receives annually approximately 5.4 million orders from 38,000 customers.